Yeung CHT, Fong S, Malik PRV, Edginton AN. 2019. Quantifying breast milk intake by term and preterm for input into pediatric physiologically-based pharmacokinetic models. Maternal and Child Nutrition. In revision.
Yu JK, Iorio A, Chelle P, Edginton AN. 2019. A comparison of methods for prediction of pharmacokinetics across factor concentrate switching in hemophilia patients. Thrombosis Research. In press.
Malik PRV, Edginton AN. 2019. Integration of ontogeny into a physiologically-based pharmacokinetic model for monoclonal antibodies in premature infants. Journal of Clinical Pharmacology. In press.
Lippert J, Burghaus R, Edginton A, Frechen S, Karlsson M, Kovar A, Lehr T, Milligan P, Nock V, Riggs M, Schaller S, Schlender J, Schmidt S, Sevestre M, Sjorgen E, Solodenko J, Staab A, Teutonico D. 2019. Open Systems Pharmacology community – an open access, open source, open science approach to modeling and simulation in pharmaceutical sciences. Clinical Pharmacology and Therapeutics: Pharmacometrics & Systems Pharmacology. In press.
Chelle P, Yeung CHT, Croteau S, Lissick J, Balasa V, Ashburner C, Park YS, Bonanad S, Vericat JEM, Nagao A, Wynn T, Corrales-Medina F, Tran H, Sharathkumar A, Chitlur M, Sarmiento S, Edginton AN, Iorio A. 2019. Development and validation of a population pharmacokinetic model for Rurioctacog alfa pegol (Adynovate). A report on behalf of the WAPPS-Hemo investigators ad hoc subgroup. Clinical Pharmacokinetics. In press.
Malik PRV, Edginton AN. 2019. Physiologically-based pharmacokinetic modelling versus allometric scaling for the prediction of infliximab pharmacokinetics in pediatric patients. Clinical Pharmacology and Therapeutics: Pharmacometrics and Systems Pharmacology. In press.
Chelle P, Yeung CHT, Bonanad S, Muñoz J, Ozelo MC, Vericat JE, Iorio A, Spears J, Mir R, Edginton AN. 2019. Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients. Journal of Pharmacokinetics and Pharmacodynamics. In press. pp 12.
Thompson EJ, Wu H, Maharaj A, Edginton AN, Balevic SJ, Cobbaert M, Cunningham AP, Hornik CP, Cohen-Wolkowiez M. 2019. Physiologically Based Pharmacokinetic Modeling for Trimethoprim and Sulfamethoxazole in Children. Clinical Pharmacokinetics. 58(7):887-89
Carcao MD, Chelle P, Clarke E, Kim L, Tiseo L, Morfini M, Hossain T, Rand ML, Brown C, Edginton AN, Lillicrap D, Iorio A, Blanchette VS. 201 Comparative pharmacokinetics of two extended half-life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference? Journal of Thrombosis and Haemostasis. 17(7):1085-1096.
Gerhart JG, Watt KM, Edginton A, Wade KC, Salerno SN, Benjamin DK Jr, Smith PB, Hornik CP, Cohen-Wolkowiez M, Duara S, Ross A, Shattuck K, Stewart DL, Neu N, Gonzalez D; Best Pharmaceuticals for Children Act-Pediatric Trials Network Steering Committee. 2019. Physiologically-Based Pharmacokinetic Modeling of Fluconazole Using Plasma and Cerebrospinal Fluid Samples From Preterm and Term Infants. Clinical Pharmacology and Therapeutics: Pharmacometrics Systems and Pharmacology. 8(7):500-5
Yu JK, Iorio A, Edginton AN. 2019. Using pharmacokinetics for tailoring prophylaxis in peoples with hemophilia switching between clotting factor products – a scoping review. Research and Practice in Thrombosis and Haemostasis. 3(3):528-541.
Yun YE, Edginton AN. 2019. Model Qualification of the PK-Sim® pediatric module for pediatric exposure assessment of CYP450 metabolized compounds. Journal of Toxicology and Environmental Health, Part A. 82(14):789-814.
McEneny-King A, Chelle P, Foster G, Keepanasseril A, Iorio A, Edginton AN. 2019. Development and evaluation of a generic population pharmacokinetic model for standard half-life factor VIII for use in dose individualization. Journal of Pharmacokinetics and Pharmacodynamics. In press. pp 12.
Aborig M, Malik PRV, Nambiar S, Chelle P, Darko J, Mutsaers A, Edginton AN, Fleck A, Osei E, Wettig S. 2019. Biodistribution and physiologically-based pharmacokinetic modelling of gold nanoparticles in mice with interspecies extrapolation. Pharmaceutics. 11(4): E179.
Stemberger M, Kallenbach F, Schmit E, McEneny-King A, Germini F, Yeung CHT, Edginton AN, von Mackensen S, Kurnik K, Iorio A. 2019. Impact of adopting population pharmacokinetics for tailoring prophylaxis in hemophilia A patients: A historically controlled observational study. Thrombosis and Hemophilia. 119:368-376.
Balbas-Martinez V, Michelet R, Edginton AN, Meesters K, Trocóniz IF, Vermeulen A. 2019. Physiologically-based pharmacokinetic model for ciprofloxacin in children with complicated urinary tract infection. European Journal of Pharmaceutical Sciences. 128:171-179.
Neely M, Bayard D, Desai A, Kovanda L, Edginton A. 2018. Pharmacometric modeling and simulation is essential to pediatric clinical pharmacology. Journal of Clinical Pharmacology. 58(Suppl 10): S73-S85
McEneny-King A, Chelle P, Iorio A, Edginton AN. 20 The effect of unmeasurable endogenous plasma factor activity levels on factor VIII dosing in patients with severe hemophilia A. Thrombosis Research. 170:53-59.
Watt KM, Cohen-Wolkowiez M, Barrett JS, Sevestre M, Zhou P, Brouwer KLR, Edginton AN. 2018. Physiologically-based pharmacokinetic approach to determine dosing on extracorporeal life support: fluconazole in children on ECMO. Clinical Pharmacology and Therapeutics: Pharmacometrics Systems and Pharmacology. 7(10):629-637.
Iorio A, Edginton AN, Blanchette V, Blatny J, Boban A, Cnossen M, Collins P, Croteau SE, Fischer K, Hart DP, Ito S, Korth-Bradley J, Lethagen S, Lillicrap D, Makris M, Mathot R, Morfini M, Neufeld EJ, Spears J. 2018. Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: rationale and general considerations. Research and Practice in Thrombosis and Haemostasis. 20;2(3):535-548.
Malik PRV, Edginton A. 2018. Pediatric physiology in relation to the pharmacokinetics of monoclonal antibodies. Expert Opinion on Drug Metabolism and Toxicology. 14(6):585-599.
Delaney SR, Malik PRV, Stefan C, Edginton AN, Colantonio DA, Ito S. 2018. Predicting escitalopram exposure to breastfeeding infants: integrating analytical and in silico techniques. Clinical Pharmacokinetics. 57(12):1603-1611.
Edginton AN. 2018. Using physiologically based pharmacokinetic modeling for mechanistic insight: cases of reverse translation. Clinical and Translational Science. 11(2):109-111. INVITED
McEneny-King A, Chelle P, Henrard S, Hermans C, Iorio A, Edginton AN. 2017. Modeling of body weight metrics for effective and cost-efficient conventional factor VIII dosing in hemophilia A prophylaxis. Pharmaceutics. 9(4): E47. INVITED
Malik P, Phipps C, Edginton A, Blay J. 2017. Pharmacokinetic considerations for antibody-drug conjugates against cancer. Pharmaceutical Research. 34(12):2579-2595. INVITED
Salerno S, Edginton A, Cohen-Wolkowiez M, Hornik C, Watt K, Jamieson B, Gonzalez D. 2017. Development of an adult physiologically based pharmacokinetic (PBPK) model of solithromycin in plasma and epithelial lining fluid. Clinical Pharmacology and Therapeutics: Pharmacometrics Systems and Pharmacology. 6(12):814-822.
Maharaj AR, Gonzalez D, Cohen-Wolkowiez M, Hornik CP, Edginton AN. 2017. Improving pediatric protein binding estimates: an evaluation of α1-acid glycoprotein maturation in healthy and infected subjects. Clinical Pharmacokinetics. 57(5):577-589.
McEneny-King A, Osman W, Edginton AN, Rao PPN. 2017. Cytochrome P450 binding studies of novel tacrine derivatives: Predicting the risk of hepatotoxicity. Bioorganic and Medicinal Chemistry Letters. 27(11):2443-2449.
Boerma M, Coyle, EA, Dietrich MA, Dintzner MR, Drayton SJ, Early J, Edginton AN, Horlen CK, Kirkwood CK, Lin A, Rager ML, Shah-Manek B, Welch AC, Toedter Williams N. 2017. Point/Counterpoint: Are Outstanding Leaders Born or Made? American Journal of Pharmaceutical Education. 81(3):58.
Malik P, Hamadeh A, Phipps C, Edginton AN. 2017. Population PBPK modelling of trastuzumab: A framework for quantifying and predicting inter-individual variability. Journal of Pharmacokinetics and Pharmacodynamics. 44(3):277-290.
Maharaj AR, Gonzalez D, Cohen-Wolkowiez M, Hornik CP, Edginton AN. 2017. Improving pediatric protein binding estimates: an evaluation of α1-acid glycoprotein maturation in healthy and infected subjects. Clinical Pharmacokinetics. In press.
Malik P, Phipps C, Edginton A, Blay J. 2017. Pharmacokinetic considerations for antibody-drug conjugates against cancer. Pharmaceutical Research. In press.
Iorio A, Edginton AN. 2017. Exploring some intersections between pharmacokinetics, factor VIII measurement, and human morphometrics – impact of recent advances in hemophilia study design on our understanding of optimal hemophilia treatment. Hemophilia. 23(4):488-490.
Offman E, Edginton AN. 2017. Pharmacokinetic time course scaling of a subcutaneously administered pegylated peptide conjugate for a first-in-human investigation. European Journal of Drug Metabolism and Pharmacokinetics. 42(1):69-78.
Edginton AN, Zimmerman EI, Vasilyeva A, Baker SD, Panetta JC. 2016. Sorafenib metabolism, transport, and enterohepatic recycling: physiologically basedmodeling and simulation in mice. Cancer Chemother Pharmacol. 77(5): 1039-52.
Offman E, Edginton AN. 2015. A PBPK workflow for first-in-human dose selection of a subcutaneously administered pegylated peptide. Journal of Pharmacokinetics and Pharmacodynamics. 42(2):135-50
Maharaj A, Fotaki N, Edginton A. 2015. Parameterization of small intestinal water volume using PBPK modeling. European Journal of Pharmaceutical Science. 67:55-64.
McEneny-King A, Edginton AN, Rao PP. 2015. Investigating the binding interactions of the anti-Alzheimer's drug donepezil with CYP3A4 and P-glycoprotein. Bioorganic & Medicinal Chemistry Letters. 25(2):297-301.
Hu Z, Edginton AN, Laizure SC, Parker RB. 2014. Physiologically based pharmacokinetic modeling of impaired carboxylesterase-1 activity - Effects on oseltamivir disposition. Clinical Pharmacokinetics. 53(9): 825-836.
Yun YE, Cotton C, Edginton AN. 2014. Development of a decision tree to classify the most accurate tissue-specific tissue to plasma partition coefficient algorithm for a given compound. Journal of Pharmacokinetics and Pharmacodynamics. 41(1): 1-14.
Maharaj AR, Edginton AN. 2014. Physiologically based pharmacokinetic modeling and simulation in pediatric drug development. Clinical Pharmacology and Therapeutics: Pharmacometrics Systems Pharmacology. 3:e150.
Edginton AN, Shah B, Sevestre M, et al. The Integration of Allometry and Virtual Populations to Predict Clearance and Clearance Variability in Pediatric Populations over the Age of 6 Years. Clinical Pharmacokinetics 2013; 52(8): 693-703.
Maharaj AR, Barrett JS, Edginton AN. A workflow example of PBPK modeling to support pediatric research and development: case study with lorazepam. AAPS J 2013;15(2):455-464.
Offman E, Edginton AN. Contrasting toxicokinetic evaluations and interspecies pharmacokinetic scaling approaches for small molecules and biologics: applicability to biosimilar development. Xenobiotica 2013; 43(6):561-569.
Edginton AN, Willmann S. Physiology-based simulations of a pathological condition: prediction of pharmacokinetics in patients with liver cirrhosis. Clin Pharmacokinet 2008; 47(11):743-752.
Willmann S, Hohn K, Edginton A, et al. Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. J Pharmacokinet Pharmacodyn 2007; 34(3):401-431.
Edginton AN, Schmitt W, Willmann S. Development and evaluation of a generic physiologically based pharmacokinetic model for children. Clin Pharmacokinet 2006; 45(10):1013-1034.
Edginton AN, Schmitt W, Voith B, et al. A mechanistic approach for the scaling of clearance in children. Clin Pharmacokinet 2006; 45(7):683-704.
Publications – Educational Research
Edginton AN, Power M, Stark A, Holbrook J. 2012. Using student feedback to design a more effective clinical biochemistry course component. Currents in Pharmacy Teaching and Learning. In press.
Edginton AN, Holbrook J. 2010. A Blended Learning Approach to Teaching Basic Pharmacokinetics and the Significance of Face-to-Face Interaction. American Journal of Pharmaceutical Education. 74(5): 88.